Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

1,785 Followers

Allogene Therapeutics (ALLO) Ownership Overview

6.69% Insiders

9.10% Mutual Funds

23.39% Other Institutional Investors

11.96% ETFs

48.86% Public Companies and

Individual Investors

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 44.45% of the company’s stock is owned by Institutional Investors, 6.69% is owned by Insiders, and 48.86% is owned by Public Companies and Individual Investors.

The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 32.49% of the company’s stock is owned by Institutional Investors, 6.69% is owned by Insiders, and 11.96% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date	Name	Activity	Value

Show More Insider Trading Activity >

Recent Hedge Fund Trading Activity

Date	Firm	Activity	Value
Mar 31, 2024	Graham Capital Management, L.p.	xxxxxxxxxxxxx	$105564
Mar 31, 2024	Primecap Management Co	xxxxxxxxxxxxx	$20446810
Mar 31, 2024	Woodline Partners Lp	xxxxxxxxxxxxx	$8542630

Show More Hedge Fund Trading Activity >

Top Shareholders

Holder	# of Shares	Type	% Holding	Value
	13,478,241	Institution	3.90%	27,630,394
	13,286,828	Institution	3.85%	27,237,997
	11,009,103	Insider	3.19%	22,568,661
Theofanis Kolokotrones	8,379,840	Institution	2.43%	17,178,672
	8,174,470	Institution	2.37%	16,757,663
	8,063,795	Insider	2.34%	16,530,780
	6,761,053	Institution	1.96%	13,860,159
	5,364,570	Institution	1.55%	10,997,368
	3,830,998	Institution	1.11%	7,853,546
Michael Rockefeller	3,501,078	Institution	1.01%	7,177,210

Top Mutual Fund Holders

# of Shares	Type	% Holding	Value
6,761,053	Institution	1.96%	13,860,159
5,364,570	Institution	1.55%	10,997,368
3,830,998	Institution	1.11%	7,853,546
2,745,270	Institution	0.80%	5,627,803
2,045,343	Institution	0.59%	4,192,953
1,733,105	Institution	0.50%	3,552,865
1,724,476	Institution	0.50%	3,535,176
1,401,115	Institution	0.41%	2,872,286
1,208,862	Institution	0.35%	2,478,167
885,754	Institution	0.26%	1,815,796

Top ETF Holders

Holder	# of Shares	Type	% Holding	Value
SPDR S&P BIOTECH ETF	12,241,809	Institution	3.55%	25,340,545
Vanguard Total Stock Market ETF	8,427,791	Institution	2.44%	18,288,306
iShares Russell 2000 ETF	3,642,600	Institution	1.06%	7,467,330
Vanguard Extended Market ETF	2,846,281	Institution	0.82%	6,176,430
iShares Biotechnology ETF	1,769,750	Institution	0.51%	3,627,988
Fidelity Enhanced Small Cap ETF	1,432,467	Institution	0.42%	2,965,207
iShares Russell 2000 Value ETF	1,362,827	Institution	0.39%	2,793,795
Schwab U.S. Small-Cap ETF	1,330,256	Institution	0.39%	2,753,630
SPDR S&P Kensho New Economies Composite ETF	1,313,100	Institution	0.38%	2,718,117
Dimensional U.S. Small Cap ETF	1,028,485	Institution	0.30%	2,128,964

FAQ

Who Owns Allogene Therapeutics (ALLO)?

According to the latest TipRanks data, approximately 23.39% of the company's stock is held by institutional investors, 6.69% is held by insiders, and 48.86% is held by retail investors.

What percentage of Allogene Therapeutics (ALLO) stock is held by institutional investors?

According to the latest TipRanks data, approximately 23.39% of Allogene Therapeutics (ALLO) stock is held by institutional investors.

What percentage of Allogene Therapeutics (ALLO) stock is held by retail investors?

According to the latest TipRanks data, approximately 48.86% of Allogene Therapeutics (ALLO) stock is held by retail investors.

Who owns the most shares of Allogene Therapeutics (ALLO)?

Vanguard owns the most shares of Allogene Therapeutics (ALLO).

What is the significance of the ownership structure for a publicly traded company?

The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.